Nektar Therapeutics
NKTR59.920USD
-5.010-7.72%
Close 11/03, 16:00（ET）Quotes delayed by 15 min
746.44MMarket Cap
LossP/E TTM
More Details of Nektar Therapeutics Company
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Nektar Therapeutics Info
Ticker SymbolNKTR
Company nameNektar Therapeutics
IPO dateMay 03, 1994
CEOMr. Howard W. Robin
Number of employees61
Security typeOrdinary Share
Fiscal year-endMay 03
Address455 Mission Bay Boulevard South
CitySAN FRANCISCO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94158
Phone18554826587
Websitehttps://www.nektar.com/
Ticker SymbolNKTR
IPO dateMay 03, 1994
CEOMr. Howard W. Robin
Company Executives of Nektar Therapeutics
Name
Name/Position
Position
Shareholding
Change
Mr. Howard W. Robin
Mr. Howard W. Robin
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
41.83K
-32.35%
Dr. Jonathan Zalevsky, Ph.D.
Dr. Jonathan Zalevsky, Ph.D.
Senior Vice President, Chief Research and Development Officer
Senior Vice President, Chief Research and Development Officer
15.15K
-12.71%
Mr. Jeffrey Robert (Jeff) Ajer
Mr. Jeffrey Robert (Jeff) Ajer
Independent Director
Independent Director
2.28K
--
Dr. Diana M. Brainard, M.D.
Dr. Diana M. Brainard, M.D.
Independent Director
Independent Director
--
--
Mr. R. Scott Greer
Mr. R. Scott Greer
Independent Director
Independent Director
--
--
Mr. Robert B. (Rob) Chess
Mr. Robert B. (Rob) Chess
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Sandra A. Gardiner
Ms. Sandra A. Gardiner
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mr. Mark A. Wilson, J.D.
Mr. Mark A. Wilson, J.D.
Senior Vice President, Chief Legal Officer
Senior Vice President, Chief Legal Officer
--
--
Mr. Corey Davis
Mr. Corey Davis
Managing Director
Managing Director
--
--
Mr. Roy A. Whitfield
Mr. Roy A. Whitfield
Lead Independent Director
Lead Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Howard W. Robin
Mr. Howard W. Robin
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
41.83K
-32.35%
Dr. Jonathan Zalevsky, Ph.D.
Dr. Jonathan Zalevsky, Ph.D.
Senior Vice President, Chief Research and Development Officer
Senior Vice President, Chief Research and Development Officer
15.15K
-12.71%
Mr. Jeffrey Robert (Jeff) Ajer
Mr. Jeffrey Robert (Jeff) Ajer
Independent Director
Independent Director
2.28K
--
Dr. Diana M. Brainard, M.D.
Dr. Diana M. Brainard, M.D.
Independent Director
Independent Director
--
--
Mr. R. Scott Greer
Mr. R. Scott Greer
Independent Director
Independent Director
--
--
Mr. Robert B. (Rob) Chess
Mr. Robert B. (Rob) Chess
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
No Data
By RegionUSD
Name
Revenue
Proportion
Rest of world
97.05M
98.60%
United States
1.38M
1.40%
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Sep 10
Updated: Wed, Sep 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BVF Partners L.P.
6.71%
The Vanguard Group, Inc.
4.99%
Nantahala Capital Management, LLC
3.73%
Millennium Management LLC
3.00%
Emerald Advisers LLC
2.93%
Other
78.64%
Shareholders
Shareholders
Proportion
BVF Partners L.P.
6.71%
The Vanguard Group, Inc.
4.99%
Nantahala Capital Management, LLC
3.73%
Millennium Management LLC
3.00%
Emerald Advisers LLC
2.93%
Other
78.64%
Shareholder Types
Shareholders
Proportion
Hedge Fund
22.02%
Investment Advisor
17.56%
Investment Advisor/Hedge Fund
9.93%
Research Firm
1.83%
Individual Investor
0.71%
Family Office
0.23%
Venture Capital
0.08%
Pension Fund
0.01%
Other
47.63%
Institutional Shareholding
Updated: Sun, Oct 5
Updated: Sun, Oct 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
340
9.78M
51.45%
-2.35M
2025Q2
342
8.92M
53.56%
-2.95M
2025Q1
408
8.48M
68.15%
-4.47M
2024Q4
427
136.20M
73.84%
-69.28M
2024Q3
442
143.71M
78.07%
-57.20M
2024Q2
458
138.43M
75.38%
-54.08M
2024Q1
477
115.32M
62.79%
-91.21M
2023Q4
499
122.94M
64.45%
-94.24M
2023Q3
522
148.15M
77.94%
-68.45M
2023Q2
531
142.56M
75.34%
-88.27M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BVF Partners L.P.
1.28M
6.71%
+1.28M
--
Jul 01, 2025
The Vanguard Group, Inc.
729.49K
3.84%
-91.15K
-11.11%
Jun 30, 2025
Nantahala Capital Management, LLC
709.76K
3.73%
+190.49K
+36.68%
Jun 30, 2025
Millennium Management LLC
649.03K
3.41%
+496.45K
+325.35%
Jun 30, 2025
Emerald Advisers LLC
143.29K
0.75%
+389.00
+0.27%
Sep 30, 2025
AQR Capital Management, LLC
427.87K
2.25%
+185.14K
+76.28%
Jun 30, 2025
Acadian Asset Management LLC
420.96K
2.21%
-65.82K
-13.52%
Jun 30, 2025
Balyasny Asset Management LP
386.29K
2.03%
+329.62K
+581.60%
Jun 30, 2025
PRIMECAP Management Company
299.72K
1.58%
-57.25K
-16.04%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
297.81K
1.57%
-576.08K
-65.92%
Jun 30, 2025
View more
Related ETFs
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Name
Proportion
Invesco Dorsey Wright Healthcare Momentum ETF
4.32%
Simplify Health Care ETF
2.66%
SPDR S&P Pharmaceuticals ETF
1.39%
Simplify Propel Opportunities ETF
1.38%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.04%
Invesco NASDAQ Future Gen 200 ETF
0.93%
Invesco Dorsey Wright SmallCap Momentum ETF
0.83%
iShares U.S. Pharmaceuticals ETF
0.4%
Invesco RAFI US 1500 Small-Mid ETF
0.12%
Fidelity Enhanced Small Cap ETF
0.06%
View more
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion4.32%
Simplify Health Care ETF
Proportion2.66%
SPDR S&P Pharmaceuticals ETF
Proportion1.39%
Simplify Propel Opportunities ETF
Proportion1.38%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.04%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.93%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.83%
iShares U.S. Pharmaceuticals ETF
Proportion0.4%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.12%
Fidelity Enhanced Small Cap ETF
Proportion0.06%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
